Lenvatinib NEW
Price | $8905 | $8700 | $8200 |
Package | 1kg | 100kg | 500kg |
Min. Order: | 1kg |
Supply Ability: | 5000 |
Update Time: | 2024-12-12 |
Product Details
Product Name: Lenvatinib | CAS No.: 417716-92-8 |
EC-No.: 1592732-453-0 | Min. Order: 1kg |
Purity: 99% | Supply Ability: 5000 |
Release date: 2024/12/12 |
lenvatinib, trade name :Lenvima, is an oral multi-target tyrosine kinase (RTK) inhibitor that can selectively inhibit the kinase activity of vascular endothelial growth factor (VEGF) receptors in addition to inhibiting the RTK associated with the pro-angiogenesis and carcinogenic signaling pathways. These include VEGF1, VEGF2, VEGF3, as well as FGFR, PDGFRα, KIT and RET. The drug was approved by the US FDA on February 13, 2015 for the treatment of locally relapsed or metastatic, radioiodine-refractory, and progressive differentiated thyroid cancer (DTC). Levatinib is a multi-target TKI that targets vascular endothelial growth factor (VEGF) receptors VEGFR1, VEGFR2, and VEGFR3. In addition to their normal cellular function, lovatinib also inhibits other TKI involved in pathologic angiogenesis, tumor growth, and the progression of cancer Chemicalbook disease, including fibroblastic growth factor receptor (FGFR) 1-4, platelet-derived growth factor receptor alpha (PDGFRα), KIT, and RET. In vitro tests, it is the most effective on VEGFR2 and VEGFR3, with IC50 of 4nM and 5.2nM, respectively, and the effect on VEGFR1 is slightly weaker (22nM). The selectivity of VEGFR2 and VEGFR3 is about 10 times higher than that of FGFR1 and PDGFRα/β. The dose-increment study of Phase I clinical trial in patients with advanced solid tumor showed that this drug can significantly change the number of circulating endothelial cells (CEC) and circulating progenitor cells (CEP), which is related to the treatment of this drug. Another Phase I clinical trial showed a significant association between tumor shrinkage and changes in biomarker levels (VEGF, SDF1α, and VEGFR2) and dose of levatinib
Company Profile Introduction
You may like
Recommended supplier
Product name | Price | Suppliers | Update time | |
---|---|---|---|---|
$1.00/1KG |
VIP6Y
|
Hebei Weibang Biotechnology Co., Ltd
|
2024-11-25 | |
$0.00/10g |
VIP3Y
|
HangZhou RunYan Pharma Technology Co.,LTD.
|
2024-11-23 | |
$40.00/5mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2024-11-19 | |
$0.00/5mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-23 | |
$5.00/1KG |
VIP4Y
|
Hebei Chuanghai Biotechnology Co,.LTD
|
2024-08-21 | |
$1000.00/1ton |
VIP1Y
|
HEBEI SHENGSUAN CHEMICAL INDUSTRY CO.,LTD
|
2024-08-14 | |
$1.00/1g |
VIP1Y
|
Apeloa production Co.,Limited
|
2024-06-19 | |
$0.00/1kg |
Nanjing Fred Technology Co., Ltd
|
2023-12-19 | ||
$60.00/1kg |
VIP2Y
|
Zibo Hangyu Biotechnology Development Co., Ltd
|
2023-10-30 | |
$0.00/1KG |
VIP2Y
|
SHANDONG BOYUAN PHARMACEUTICAL CO., LTD.
|
2023-09-07 |
- Since: 2021-05-08
- Address: Room 10-0-1001, Chunbei District, Shunde North Road, Xiangdu District, Xingtai city, Hebei Province
+86-13910575315
admin@hbdangtong.com